Maxim Group analyst Jason McCarthy maintained a Buy rating on Theriva Biologics (TOVX – Research Report) yesterday and set a price target of $4.00. The company’s shares closed yesterday at $0.62.
According to TipRanks, McCarthy is an analyst with an average return of -38.8% and a 14.29% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Actinium Pharmaceuticals, and Daré Bioscience.
Currently, the analyst consensus on Theriva Biologics is a Moderate Buy with an average price target of $4.00.
See Insiders’ Hot Stocks on TipRanks >>
TOVX market cap is currently $10.17M and has a P/E ratio of -0.51.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.
Read More on TOVX:
